Please use this identifier to cite or link to this item:
Title: Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: A randomized study
Authors: Nunes, Gilberto L.
Abizaid, Alexandre C.
Theodoro, Marcus P.
Brito, Fabio S.
Caixeta, Adriano
Silva, Luis Felipe F. da
Mazzotti, Nicolle G.
Bello-Klein, Adriane
Clausell, Nadine
Hosp Sao Francisco
Inst Dant Pazzanese Cardiol
Universidade Federal de São Paulo (UNIFESP)
Hosp Israelita Albert Einstein
Hosp Barra Or
Univ Fed Rio Grande Sul
Issue Date: 1-Nov-2006
Publisher: Mosby, Inc
Citation: American Heart Journal. St Louis: Mosby, Inc, v. 152, n. 5, 7 p., 2006.
Abstract: Background Oxygen-free radicals can stimulate smooth muscle cell proliferation and may therefore be involved in the genesis of in-stent restenosis. Thus, treatment with probucol, a potent antioxidant agent that has been shown to reduce restenosis after balloon angioplasty, may be an effective strategy to prevent intimal hyperplasia after stenting.Methods in a prospective double-blind study, 59 patients submitted to coronary stent implantation were randomly assigned to treatment with either probucol (1 g/d) or placebo, starting two weeks before the procedure and continued for 6 months. the primary end point was the intimal hyperplasia volume at 6 months measured by intravascular ultrasound (IVUS) imaging.Results of the 59 randomized patients, 54 underwent successful stent implantation, completed the follow-up period, and underwent repeat angiography, 6.1 +/- 1.1 months after the procedure. Volumetric IVUS analysis revealed similar intimal hyperplasia volumes (40.3 +/- 26.7 mm(3) for probucol vs 44.8 +/- 28.3 mm(3) for placebo) and percent volume obstruction of the lumen (30.4%+/- 14.5% for probucol versus 30.7%+/- 17.2% for placebo) in both groups. in addition, quantitative coronary angiography showed no differences in late loss (1.0 +/- 0.8 mm vs 1.1 +/- 0.8 mm), loss index (0.5 +/- 0.4 for both groups), or angiographic restenosis rates (19.4% vs 18.5%) between the probucol and placebo groups, despite the observation of significant changes in the lipid profile and in the plasma antioxidant defenses in patients receiving probucol.Conclusions Treatment with the antioxidant probucol failed to reduce neointimal formation after coronary stent implantation as assessed by IVUS volumetric analysis.
ISSN: 0002-8703
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.